Key Players
Competitive Landscape
Four supplier models shape competition in the heart failure drugs market: global cardiometabolic groups, cardiovascular franchise owners, indication-focused developers and regional commercialization partners. Their positions differ by labeled population and evidence breadth plus the ability to sustain treatment across hospital discharge and community follow-up.
Commercial investment has moved in two directions since 2025, into broader ejection-fraction indications and into licensed expansion beyond established markets. Bayer received USA approval for finerenone in July 2025 for adults with LVEF of at least 40%. Lexicon Pharmaceuticals shipped its first commercial INPEFA order to Viatris in the United Arab Emirates in November 2025. Price remains relevant, but health systems first compare labeled coverage and outcomes evidence plus access support across care settings.
Company developments mapped to drivers, trends and opportunities (2026-2036)
| Development | Driver | Trend | Opportunity |
|---|---|---|---|
| Lexicon Pharmaceuticals, Inc. shipped the first commercial INPEFA order to Viatris in the United Arab Emirates in November 2025 following local approval. | Licensees need approved supply and launch inventory before physicians can convert a new national authorization into routine prescriptions. | Indication-focused developers are extending heart failure franchises through regional partners instead of building every commercial network directly. | Revenue is available from milestone income and product supply across approved markets outside the United States and Europe. |
| Merck & Co., Inc. reported Phase 3 VICTOR results for VERQUVO in August 2025. The trial enrolled 6,105 stable chronic HFrEF patients and missed its primary endpoint. | Clinicians require evidence that separates worsening heart failure populations from stable ambulatory patients receiving contemporary foundational therapy. | Companies are testing narrower treatment positions against better treated populations rather than assuming approved benefits transfer across every HFrEF stage. | Commercial value remains concentrated in clearly defined worsening-heart-failure populations supported by outcomes evidence and specialist selection. |
| Bayer AG received USA FDA approval for finerenone in adults with heart failure and LVEF of at least 40% in July 2025. | Cardiology teams need disease-modifying options for mildly reduced and preserved ejection-fraction populations that remain at risk of hospitalization. | Mineralocorticoid receptor treatment is expanding beyond traditional HFrEF pathways into broader cardiorenal populations with defined labeling. | Revenue is available through hospital initiation and continuing outpatient use among eligible adults with HFmrEF or HFpEF. |
AstraZeneca PLC, Boehringer Ingelheim International GmbH, Eli Lilly and Company and Otsuka Pharmaceutical Co., Ltd. compete on indication breadth and prescribing-transition support. No table-eligible launch, approval, shipment or completed transaction was identified for these four during January 2025 to August 2026.
Source: Future Market Insights, Heart Failure Drugs Market and Cardiometabolic Drugs Market reports, 2026-2036.
The listed companies collectively cover SGLT2 inhibition and ARNI treatment plus mineralocorticoid receptor and soluble guanylate cyclase pathways alongside Lexicon's dual SGLT1 and SGLT2 inhibition and Otsuka's Japan-specific formulation support.
Who leads the Heart Failure Drugs Market?
No single company leads every drug class or ejection-fraction group within the defined heart failure drugs market. AstraZeneca and the Boehringer Ingelheim-Eli Lilly alliance compete across broad SGLT2 heart failure labels. Novartis anchors the ARNI pathway, and Bayer holds the July 2025 USA indication expansion for finerenone.
Which suppliers hold recent heart failure regulatory approvals?
Bayer holds the July 2025 USA approval for finerenone in adults with LVEF of at least 40%. Lexicon reported the first approved market outside the United States for INPEFA in 2025. Novartis and Otsuka support the pediatric Entresto formulation approved and launched in Japan during 2024.
Which companies provide products across HFrEF and broader ejection-fraction groups?
AstraZeneca supplies dapagliflozin and Boehringer Ingelheim with Eli Lilly supplies empagliflozin across broad heart failure populations. Novartis provides sacubitril and valsartan for established ARNI treatment, and Bayer covers LVEF of at least 40% as Merck serves worsening chronic HFrEF through vericiguat.
Which suppliers serve the United States and international heart failure markets?
AstraZeneca and Novartis plus Boehringer Ingelheim, Eli Lilly, Bayer and Merck operate cardiovascular franchises with broad international regulatory and commercial coverage. Lexicon markets INPEFA in the United States and supplies licensed markets through Viatris, and Otsuka works with Novartis on Entresto commercialization and pediatric formulation support in Japan.
Representative Company Overview
| Company | Positioning | Verified market-relevant capabilities |
|---|---|---|
| AstraZeneca PLC | Global | Dapagliflozin franchise covering heart failure treatment and event-risk reduction across cardiometabolic populations. The 2025 annual report confirms continued global cardiovascular commercialization. |
| Novartis AG | Global | Sacubitril and valsartan ARNI franchise for chronic heart failure plus continuing clinical evidence in defined HFrEF populations. The company presented PARACHUTE-HF data at ESC 2025. |
| Boehringer Ingelheim International GmbH | Global | Empagliflozin heart failure franchise developed and commercialized with Eli Lilly across ejection-fraction categories and related cardiorenal populations. |
| Eli Lilly and Company | Global | Commercial partner for empagliflozin with Boehringer Ingelheim, supporting international evidence communication and commercialization across cardiorenal populations. |
| Bayer AG | Global | Finerenone for adults with heart failure and LVEF of at least 40% following USA FDA approval in July 2025. |
| Merck & Co., Inc. | Global | Vericiguat for symptomatic chronic HFrEF following a recent worsening event plus completed VICTORIA and VICTOR outcome programs. |
| Lexicon Pharmaceuticals, Inc. | United States and licensed international markets | Sotagliflozin for heart failure risk reduction under the INPEFA brand. The first commercial UAE order was shipped to Viatris in November 2025. |
| Otsuka Pharmaceutical Co., Ltd. | Japan and selected Asian markets | Co-promotion and formulation support for sacubitril and valsartan in Japan. Pediatric Entresto granules were launched with Novartis in May 2024. |
Research Methodology
The companies in this section illustrate market structure and do not form a ranking across drug classes or geographies. A company appears where current official evidence confirms a heart failure medicine or directly related commercialization role. Evidence includes annual reports and regulatory decisions plus clinical readouts and company announcements from the named legal entities. Regulatory approvals belong to the medicine and entity named by the authority, and 2026 segment shares remain Future Market Insights estimates for the defined market scope.
